{"id":"infliximab-adalimumab-y-golimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Tuberculosis reactivation"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab, adalimumab, and golimumab are monoclonal antibodies or fusion proteins that bind to and neutralize TNF-alpha, preventing its interaction with TNF receptors on immune cells. This reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-alpha production, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.","oneSentence":"These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:45.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT05313620","phase":"PHASE4","title":"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2022-04-01","conditions":"Ulcerative Colitis, Thromboembolism","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Infliximab Adalimumab y Golimumab","genericName":"Infliximab Adalimumab y Golimumab","companyName":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","companyId":"fundaci-n-de-investigaci-n-biom-dica-hospital-universitario-de-la-princesa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}